No treatment-related serious adverse events were observed in the study. Hearing function was tested over the course of 90 days following dosing. This included a subset of subjects that more than doubled their WR scores. The single dose had a favorable safety profile and was well tolerated. Validated measures of hearing including WR, WIN, and pure tone audiometry will be used. We expect to share results from this clinical trial in the second quarter of 2021. Hearing aids also cannot repair the underlying pathology of hearing loss. There are also further direct and indirect impacts on individuals suffering from SNHL. Humans are born with about 15,000 hair cells in the cochlea of each ear. 8226; Difficulties with background noise. FX-322 was observed to be well-tolerated in this trial. A p value is the probability that the difference between two data sets was due to chance. Despite the change, the results were consistent with the figure above. & & Group three received four injections of FX-322. We are pursuing this and other approaches to stimulating myelination of axons in MS. We also have the right to grant sublicenses under the Cambridge License. Upon entering into the Cambridge License, we made a $50.0 thousand license fee payment. We have the right to terminate for any reason upon 90 days' prior written notice. There are three manufacturers of cochlear implants that market in the United States. Some preclinical testing may continue even after the IND is submitted. We are a clinical-stage biotechnology company with a limited operating history. We were established and began operations in 2014. We or Astellas may not be in a position to do so for several years, if ever. As a result, increasingly high barriers are being erected to the entry of new products. In addition, the CCPA went into effect on January 1, 2020. These changes may lead to additional costs and increase our overall risk exposure.
